#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@megadoctornews.comFDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer #AnktivaNogapendekinAlfaInbakiceptPmln #BladderCancer #cancer #CancerTreatment #FdaApproval #MegaDoctorNews #RioGrandeValley
@agentictribune.bsky.socialFDA Expands Use of Anktiva to Treat High-Grade Papillary Non‑Muscle Invasive Bladder Cancer
@abcuk.bsky.socialThank you to everyone who joined our ABC UK Annual Nurse Education Day on 25 September!
Congratulations to Craig J, winner of our £335 M&S voucher prize draw!
Sign up to our newsletter for details of next year’s event: actionbladdercanceruk.org/newsletter/
@drtimos.bsky.social🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVsc9b !
@jamaoncology.comAmong patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up.
@vcclibrary.bsky.socialDisitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non–Muscle-Invasive #BladderCancer: A Nonrandomized Clinical Trial. jamanetwork.com/journals/jam...
@jamaoncology.comAmong patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up.
@drtimos.bsky.social🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVkgfk !
@uicancercenter.bsky.socialCancer Center member Karine Tawagi, MD, a practicing medical oncologist at @uihealth.bsky.social, discussed evolving treatments in muscle-invasive #bladdercancer on an episode of MedNews Week, presented in partnership with @oncodaily.bsky.social TV.
Watch here: https://bit.ly/4dJhjRz
@abcuk.bsky.socialA big thank you to Di & the amazing team at Kent & Canterbury for hosting our #ABCUK stall today for #UrologyAwarenessMonth
Special thanks to Erick, Urology Suite Manager, who joined us on his day off, and to Mr Papadopoulos for popping down to say hello!
@abcuk.bsky.socialWhat an amazing 5th Annual Nurse Education Day in Birmingham on Friday!
A huge congratulations to Diane Leach, our ABC UK Nurse of the Year 2026! Nominated by 3 colleagues, this recognition is a wonderful testament to her dedication and impact. Well done, Diane!
@oncoalert.bsky.social🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update
Source: AstraZeneca
Submission is supported by VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and OS
@abcuk.bsky.socialDr Anna Wilkins - Honorary Consultant at @royalmarsden.org & Niyati Lobo, Consultant Urologist at
Cambridge University Hospitals on 'Is radical cystectomy or radical chemo-radiation the treatment of choice for muscle-invasive bladder cancer in the modern era?'
#bladdercancer #nurseeducation
@abcuk.bsky.socialLovely photos of one of our Trustees, Jenny Akins, with Lizzy Rowland and Carmen Hayes.
@abcuk.bsky.socialThanks to Ellie Stewart, Gynaecology Matron & CNS Urogynaecology at @westsuffolknhs.bsky.social
for presenting 'The menopausal bladder.' Giving nurses a better understanding of the role of oestrogen on the bladder and lower urinary tract.
@abcuk.bsky.socialPaula Allchorne, Urology Lead Nurse at Barts Health, presented 'Beyond survival: psychosexual wellbeing in women - living with and beyond bladder cancer' after lunch.
@abcuk.bsky.socialLunchtime - food, networking, discussions and work!
It's lovely to see people making new connections, and sharing their best practice.
@abcuk.bsky.social4 difficult cases - presentations by Jess Codling of Barts Health, Jenny Akins of Royal Wolverhampton NHS Trust, Sally Allison of The Dudley Group NHS Foundation Trust and Lizzy Rowland from Surrey and Sussex Healthcare NHS Trust, before lunch.
@pharmaphorum.bsky.social#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug.
